Print

Durata Therapeutics, Inc. Completes Target Enrollment in Phase 3 DISCOVER 1 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in abSSSI Patients  
9/6/2012 10:16:00 AM

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that it has completed its target enrollment for DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”), one of two ongoing, global, Phase 3 clinical trials of Durata’s lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).
//-->